ELITE PHARMACEUTICALS, INC /NV/ — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+119.9% +$17M
$32M
Cost of Revenue↑+126.0% +$10M
$19M
Gross Profit↑+111.7% +$7M
$13M
R&D↓-42.0% -$753K
$1M
D&A↓-14.2% -$44K
$269K
Operating Income↑+721.0% +$8M
$9M
EBITDA↑+557.9% +$8M
$9M
Interest Expense↓-11.6% -$4K
$27K
Interest Income↑+1541.8% +$79K
$84K
Other Income/Expense↑+200.3% +$23M
$12M
Pretax Income↑+295.6% +$31M
$21M
Tax Provision↑+836.5% +$2M
$2M
Net Income↑+270.7% +$29M
$19M
Gross Margin↓-1.6pts
41.0%
Operating Margin↑+20.9pts
28.5%
Net Margin↑+134.7pts
58.9%
Effective Tax Rate↑+13.0pts
10.8%
Deferred Tax Assets↓-39.1% -$9M
$13M
DTA Valuation Allowance
—
Operating Lease Cost
—
Revenue YoY Variation↑+127.5pts
119.9%
Income YoY Variation↑+789.9pts
721.0%
Revenue QoQ Variation↑+10.9pts
-13.0%
Income QoQ Variation↑+78.2pts
9.7%